Poseida Therapeutics Inc. (PSTX) Financial Statements (2025 and earlier)

Company Profile

Business Address 9390 TOWNE CENTRE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:237,800198,600212,200238,800214,600247,200
Cash and cash equivalents30,54553,29744,47225,50349,91140,144
Short-term investments207,267145,349167,730213,334164,695207,057
Other undisclosed cash, cash equivalents, and short-term investments(12)(46)(2)(37)(6)(1)
Receivables12,42712,0279,0108,67211,9068,437
Prepaid expense   3,707   
Other undisclosed current assets4,1096,1051,5585,1923,6895,059
Total current assets:254,336216,732226,475252,664230,195260,696
Noncurrent Assets
Operating lease, right-of-use asset19,96220,85521,72622,57123,39624,208
Property, plant and equipment17,75918,36419,05520,38221,01122,114
Intangible assets, net (including goodwill)5,5485,5485,5485,5485,5485,548
Goodwill4,2284,2284,2284,2284,2284,228
Intangible assets, net (excluding goodwill)1,3201,3201,3201,3201,3201,320
Other noncurrent assets1,0811,0811,0811,0871,0651,055
Total noncurrent assets:44,35045,84847,41049,58851,02052,925
TOTAL ASSETS:298,686262,580273,885302,252281,215313,621
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15,16512,40319,73814,93513,17013,283
Accounts payable2,9902,7043,2672,5422,0973,200
Accrued liabilities12,1759,69916,47112,39311,07310,083
Deferred revenue63,28949,77031,00844,81020,23320,090
Other undisclosed current liabilities23,98022,59020,57217,22816,48515,317
Total current liabilities:102,43484,76371,31876,97349,88848,690
Noncurrent Liabilities
Long-term debt and lease obligation58,79658,69158,59058,49158,40258,322
Long-term debt, excluding current maturities58,79658,69158,59058,49158,40258,322
Liabilities, other than long-term debt76,63934,53240,27643,12833,63245,052
Deferred revenue54,92411,90316,78018,7878,46119,061
Other liabilities2,8972,7542,6142,4782,3552,245
Operating lease, liability18,81819,87520,88221,86322,81623,746
Other undisclosed noncurrent liabilities     3,9923,992
Total noncurrent liabilities:135,43593,22398,866101,61996,026107,366
Total liabilities:237,869177,986170,184178,592145,914156,056
Equity
Equity, attributable to parent60,81784,594103,701123,660135,301157,565
Common stock1010101099
Additional paid in capital710,825703,196697,856692,792672,736667,262
Accumulated other comprehensive income (loss)(82)(47)126(200)(280)2
Accumulated deficit(649,936)(618,565)(594,291)(568,942)(537,164)(509,708)
Total equity:60,81784,594103,701123,660135,301157,565
TOTAL LIABILITIES AND EQUITY:298,686262,580273,885302,252281,215313,621

Income Statement (P&L) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Revenues25,97328,14224,9959,35220,01310,343
Gross profit:25,97328,14224,9959,35220,01310,343
Operating expenses(57,729)(52,719)(50,904)(45,574)(47,868)(49,859)
Operating income (loss):(31,756)(24,577)(25,909)(36,222)(27,855)(39,516)
Nonoperating income
(Other Nonoperating income)
2,6442,5562,8276,7872,5402,697
Interest and debt expense  (2,253)(2,267)(2,236)(2,141)(2,028)
Income (loss) from continuing operations before equity method investments, income taxes:(29,112)(24,274)(25,349)(31,671)(27,456)(38,847)
Other undisclosed loss from continuing operations before income taxes      
Income (loss) from continuing operations before income taxes:(29,112)(24,274)(25,349)(31,671)(27,456)(38,847)
Income tax expense   (107)  
Net income (loss):(29,112)(24,274)(25,349)(31,778)(27,456)(38,847)
Other undisclosed net loss attributable to parent (2,259)     
Net income (loss) available to common stockholders, diluted:(31,371)(24,274)(25,349)(31,778)(27,456)(38,847)

Comprehensive Income ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net income (loss):(29,112)(24,274)(25,349)(31,778)(27,456)(38,847)
Comprehensive income (loss):(29,112)(24,274)(25,349)(31,778)(27,456)(38,847)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2,294)(173)32680(282)151
Comprehensive income (loss), net of tax, attributable to parent:(31,406)(24,447)(25,023)(31,698)(27,738)(38,696)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: